NervGen Pharma Corp. (NGEN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for NGEN, including 2 press releases and news items and 1 SEC filing. The most recent was published Oct 16, 2026.
NGEN rankings
Financial highlights
Full financials- Net income, FY2025
- -C$44.12M
- Cash
- C$22.07M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks280%
2026-05-102026-11-01
Mix990d
- SEC Filings4(44%)
- Other3(33%)
- Offering1(11%)
- Leadership1(11%)
Latest news
25 items- SECAmendment: SEC Form 6-K/A filed by NervGen Pharma Corp.6-K/A - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECAmendment: SEC Form 40-F/A filed by NervGen Pharma Corp.40-F/A - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryRESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational designEnrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028 MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ:NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announ
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting AdjustmentsAdjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit. VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ:NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended June 30, 2026. The
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen to Host Inaugural R&D Day on September 30, 2026R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the Phase 3 RESTORE study design and rationaleFour leading experts spanning spinal cord injury clinical care, outcome assessment, translational research and community advocacy to join NervGen management for presentations and a live question-and-answer sessionLive webcast on Wednesday, September 30, 2026, beginning at 10:00 a.m. ET VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ:NGEN), a late-stage clinical biopharmaceutical company developing first-i
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesSite activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts. VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGe
- ANALYSTLeerink Partners initiated coverage on Nervgen Pharma with a new price targetLeerink Partners initiated coverage of Nervgen Pharma with a rating of Outperform and set a new price target of $10.00
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form SUPPL filed by NervGen Pharma Corp.SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)
- ANALYSTTD Cowen initiated coverage on Nervgen PharmaTD Cowen initiated coverage of Nervgen Pharma with a rating of Buy
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form EFFECT filed by NervGen Pharma Corp.EFFECT - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form SUPPL filed by NervGen Pharma Corp.SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form F-X filed by NervGen Pharma Corp.F-X - NERVGEN PHARMA CORP. (0001751912) (Subject)
- SECSEC Form F-10 filed by NervGen Pharma Corp.F-10 - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyNVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit. Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study. VA
- SECSEC Form 6-K filed by NervGen Pharma Corp.6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)
- SECSEC Form SUPPL filed by NervGen Pharma Corp.SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen Announces Pricing of US$60.0 Million Public Offering of SecuritiesVANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the d
- SECSEC Form SUPPL filed by NervGen Pharma Corp.SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)
- PRNervGen Announces Proposed Public Offering of SecuritiesThe Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase co
NGEN FAQ
8 questionsWhat is the latest news on NGEN?
In the last 30 days Quantisnow tracked 3 wire items for NGEN: 2 press releases and news items and 1 SEC filing. The most recent was published on October 16, 2026.Is NGEN profitable?
No. NervGen Pharma Corp. reported a net loss of C$44.12M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NGEN have?
NervGen Pharma Corp. reported C$22.07M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NGEN stock trade?
NervGen Pharma Corp. (NGEN) is listed on NASDAQ.What sector and industry is NGEN in?
NervGen Pharma Corp. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NGEN?
NervGen Pharma Corp. has had 3 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $10.00 price target on 2026-07-13. Recent price targets range from $10.00 to $18.00.What companies are similar to NGEN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NGEN side-by-side with any of them on Quantisnow.How can I track NGEN on Quantisnow?
Quantisnow aggregates NervGen Pharma Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NGEN to receive live email and push alerts on every new disclosure.